Led first human RCT of senolytic therapy and heads the $101M XPrize Healthspan competition
Jamie Justice is a geroscience researcher and Executive Vice President of the Health domain at the XPrize Foundation, where she leads the $101 million Healthspan Prize — a global competition to develop therapeutics that restore muscle, cognitive, and immune function by at least ten years in adults aged 65 to 80. Her scientific career has focused on translational geroscience: moving aging interventions from animal models into rigorous human clinical trials. She is the lead author of the first randomized controlled trial of senolytic therapy in humans, demonstrating that the dasatinib and quercetin combination was safe and well-tolerated in patients with idiopathic pulmonary fibrosis, with measurable improvements in physical function. She is also a key collaborator in the TAME (Targeting Aging with Metformin) trial, the first FDA-approved study designed to target aging itself as a condition rather than its individual diseases.